Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

HCW cuts Avenue Therapeutics to neutral; PT to $6 from $13

H.C. Wainwright downgraded Avenue Therapeutics (NASDAQ:ATXI) to “neutral” from “buy” and slashed its price target to $6 from $13, citing a complete response letter from the FDA for Avenue’s IV tramadol for the...

October 12, 2020

Markets

Brookline starts MEI Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of MEI Pharma (NASDAQ:MEIP) with a “buy” rating and price target of $10. The stock closed at $3.08 on Oct. 9. Analyst Leah Rush Cann writes that MEI Pharma is developing...

October 12, 2020

Markets

Stifel starts Dyne Therapeutics at buy; PT $29

Stifel initiated coverage of Dyne Therapeutics (NASDAQ:DYN) with a “buy” rating and $29 price target. The stock closed at $18.64 on Oct. 9. “We view Dyne as an emerging leader in the neuromuscular space, and our...

October 12, 2020

Developments

Axovant gets FDA rare pediatric designation for gangliosidosis gene therapy

Axovant Gene Therapies (NASDAQ:AXGT) received FDA orphan drug designation for AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal disease where mutations in the GLB1 gene...

October 9, 2020

Developments

Rigel Pharma enrolls first patients in Phase 2 COVID-19 trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patients in its Phase 2 trial evaluating fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the NIH’s National Heart, Lung...

October 9, 2020

Developments

X4 Pharma’s mavorixafor gets FDA fast track designation for WHIM syndrome

The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor fast track designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or low white...

October 8, 2020

Developments

Imagin Medical selects Lighthouse Imaging as i/Blue contract manufacturer

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) selected Lighthouse Imaging as the contract manufacturer for the i/Blue Imaging System. Lighthouse is an FDA registered and ISO 13485:2016...

October 7, 2020

Developments

Oncternal gets FDA rare pediatric disease designation for Ewing sarcoma

The FDA granted Oncternal Therapeutics’ (NASDAQ:ONCT) TK216 rare pediatric disease designation for the treatment of Ewing sarcoma. Ewing sarcoma is the second most common bone tumor among children and adolescents, with...

October 6, 2020

Developments

Corbus Pharma lenabasum flunks Phase 2b cystic fibrosis study

Corbus Pharmaceuticals (NASDAQ:CRBP) reported disappointing topline results from its Phase 2b trial of lenabasum for the treatment of cystic fibrosis. Patients were randomized to receive either 5 mg or 20 mg of...

October 6, 2020

Markets

BTIG ups Neuronetics PT to $10 from $6

BTIG raised its price target for Neuronetics (NASDAQ:STIM) to $10 from $6, citing takeaways from recent virtual investor meetings, which focused on how the company’s new CEO, Keith Sullivan, will be reshaping the...

October 6, 2020

Markets

WB starts Chinook Therapeutics at OP

William Blair initiated coverage of Chinook Therapeutics (NASDAQ:KDNY) with an “outperform” rating. The stock closed at $14.60 on Oct. 5. Chinook recently completed a merger with Aduro Biotech to become a leading...

October 6, 2020

Markets

Brookline starts Polyphor at a value of 37 CHF a share

Brookline Capital Markets initiated coverage of Swiss-based Polyphor (SWX:POLN) at a value of 37 CHF a share. The stock was quoted at 6.98 CHF on Oct. 5. Polyphor is a biopharmaceutical company focused on oncology and...

October 5, 2020

Subscribe